Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis

Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis

Patients with malignant melanoma have a 5-year survival rate of only 15–20% once the tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are initially effective for the majority of patients with melanoma harboring BRAFV600E mutation, over 90% of patients relapse wi...

Full description

Bibliographic Details
Main Authors: Marion Vanneste, Charlotte R. Feddersen, Afshin Varzavand, Elliot Y. Zhu, Tyler Foley, Lei Zhao, Kathleen H. Holt, Mohammed Milhem, Robert Piper, Christopher S. Stipp, Adam J. Dupuy, Michael D. Henry
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Oncology
Subjects:
melanoma
forward genetic screen
MAPKi resistance
CUL3 ubiquitin ligase
Rac1
Src inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00442/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00442/full

Similar Items